In an Amicus Brief submitted today in Outsourcing Facilities Association v. FDA in the U.S. District Court for the Northern District of Texas, Ivim Health raises urgent concerns over the FDA's ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

New research published in JAMA Network Open led by Truveta Research and Ezekiel Emanuel, MD, PhD, Perelman School of Medicine ...

Medical experts have long warned about alcohol's risks, and now the drinks industry is embracing sobriety, investing in ...

But with tirzepatide removed from the shortages ... The restoration of Mounjaro’s availability coincides with increasing competition in the GLP-1 space. Eli Lilly’s strategic moves to ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

Komodor, the company that automates Kubernetes operations, health, performance and cost management, today announced that over the past twelve months ended January 31, it increased annual recurring ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Could a diabetes and weight loss drug benefit the brain? Here’s what scientists are learning. By Dana G. Smith and Dani Blum Over a decade ago, a smattering of studies suggested that early ...